MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Lixisenatide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Lixisenatide (AVE0010; Adlyxin, Lyxumia) is a once-daily, short-acting GLP-1 receptor agonist for type 2 diabetes. It is a 44-amino-acid analogue of exendin-4 — the GLP-1 mimetic from Gila monster saliva — modified to resist DPP-4 and to bind the GLP-1 receptor about four-fold more tightly than native GLP-1 (PMID source: Barnett, Core Evidence 2011). It lowers glucose by enhancing glucose-dependent insulin secretion, suppressing glucagon, and markedly slowing gastric emptying, giving its strongest effect on post-meal glucose. Dosing is a simple two-step titration: 10 mcg once daily for 14 days, then 20 mcg once daily, injected within one hour before the first meal. In ELIXA (NEJM 2015, PMID 26630143) it was cardiovascular-safe but not superior to placebo, and in the LIXIPARK Phase 2 trial (NEJM 2024, PMID 38598572) it slowed motor progression in early Parkinson's disease. FDA-approved 2016 and EMA-approved 2013, it was later discontinued for commercial reasons; research vials are lab-use only.
Reconstitute: Add 3 mL bacteriostatic water → 0.33 mg/mL concentration.
Typical dose: 10 mcg/day for 14 days, then 20 mcg/day
Easy measuring: At 0.33 mg/mL, 1 unit = 0.01 mL = 0.0033 mg (3 mcg) on a U-100 insulin syringe.
Storage: Commercial prefilled pens: refrigerate at 2–8 °C before first use and protect from light; do not freeze. After the first injection, store below 30 °C and use within 14 days. Research-grade lyophilized powder: store frozen at -20 °C or refrigerated at 2–8 °C; once reconstituted, keep at 2–8 °C and use within about 14–28 days.
Half-life: ~3 hours terminal (2–4 h range); Tmax 1–3.5 h, short-acting/prandial profile, predominantly lowers post-meal glucose
Route: Subcutaneous, once daily within one hour before the first meal of the day (abdomen, thigh, or upper arm)
Status: FDA-approved Adlyxin (2016) and EMA-approved Lyxumia (2013); discontinued/withdrawn for commercial reasons — research vials are lab-use only
About Lixisenatide
Lixisenatide is a short-acting GLP-1 receptor agonist given as a once-daily subcutaneous injection. Unlike many compounds catalogued on this site, its real-world clinical route genuinely is subcutaneous, so the reconstitution figures below map directly onto how the drug is actually used [1]. Commercially it shipped as a prefilled multi-dose pen (a 50 mcg/mL green starter pen and a 100 mcg/mL burgundy maintenance pen); the vial-and-bacteriostatic-water protocol shown here is an educational reconstitution reference for research-grade lyophilized powder.\n\nThe approved Lixisenatide dosage uses a deliberately simple two-step escalation to limit gastrointestinal side effects. You start at 10 mcg once daily for 14 days, then increase to a 20 mcg once-daily maintenance dose on Day 15 [1][3]. Because lixisenatide is a prandial (short-acting) agonist with a terminal half-life of roughly 3 hours, the injection is timed within one hour before the first meal of the day, where its gastric-emptying effect blunts the post-meal glucose spike [1][2].\n\nKnowing how to dose Lixisenatide on a research vial is straightforward: reconstituting a 1 mg vial with 3 mL of bacteriostatic water yields about 333 mcg/mL, so 10 mcg measures 3 units and 20 mcg measures 6 units on a U-100 insulin syringe — both clean, measurable marks.\n\nFrequency: Inject once daily subcutaneously, within one hour before the first meal of the day; pick the same meal each day to keep the timing consistent [1].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3 mL of bacteriostatic water into a sterile syringe (this yields about 0.33 mg/mL, i.e. ~333 mcg/mL, from a 1 mg vial).
Inject the water slowly down the inner wall of the vial; do not spray directly onto the powder, and avoid foaming.
Swirl or roll the vial gently until fully dissolved and clear — never shake, as agitation can denature the peptide.
Draw your dose on a U-100 insulin syringe: 10 mcg = 3 units (0.03 mL) for the first 14 days, then 20 mcg = 6 units (0.06 mL) from Day 15.
Swab the site (abdomen, thigh, or upper arm), inject subcutaneously within one hour before the first meal, rotate sites daily, and return the vial to the refrigerator.
Interactive Lixisenatide Syringe Calculator
Currently visualizing the 1 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 1mg dry powder in 3mL water yields 0.33 mg/mL. To evaluate a 250mcg dose, pull to 75.0 units (75 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Initiation — Days 1–14 (10 mcg once daily) | 10 mcg | 3 units (0.03 mL) |
| Maintenance — Day 15 onward (20 mcg once daily) | 20 mcg | 6 units (0.06 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 1 mg vial.
Peptide Vials (Lixisenatide, 1 mg each):
- check8 weeks (10 mcg ×14d then 20 mcg/day): ~0.98 mg total ≈ 1 vial
- check12 weeks (10 mcg ×14d then 20 mcg/day): ~1.54 mg total ≈ 2 vials
- check16 weeks (10 mcg ×14d then 20 mcg/day): ~2.10 mg total ≈ 3 vials
Insulin Syringes (U-100):
- check8 weeks: 56 syringes (1 per daily injection)
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3 mL per vial for reconstitution.
- check8 weeks (1 vial): ~3 mL → 1 × 10 mL bottle
- check12 weeks (2 vials): ~6 mL → 1 × 10 mL bottle
- check16 weeks (3 vials): ~9 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer day: 2 swabs (vial stopper + injection site)
- check8 weeks: ~112 swabs → 1 × 200-count box
- check12 weeks: ~168 swabs → 2 × 100-count boxes
- check16 weeks: ~224 swabs → 3 × 100-count boxes
Mechanism of Action (MOA)
Lixisenatide is a 44-amino-acid synthetic analogue of exendin-4, the GLP-1 mimetic originally isolated from Gila monster (Heloderma suspectum) saliva. Native human GLP-1 has a half-life of only about 1–2 minutes because dipeptidyl peptidase-4 (DPP-4) rapidly cleaves it; the exendin scaffold is naturally DPP-4-resistant, and lixisenatide adds a C-terminal modification — deletion of one proline and addition of six lysine residues — that further stabilizes the molecule. The result is a peptide with roughly four-fold higher affinity for the GLP-1 receptor than native GLP-1 (IC50 ≈ 1.4 nM) and a pharmacokinetic profile suited to once-daily dosing [2].\n\nAs a GLP-1 receptor agonist, lixisenatide reproduces the incretin effect by activating the GLP-1 receptor, a G-protein-coupled receptor that signals through adenylate cyclase and cyclic AMP. At pancreatic beta cells this stimulates glucose-dependent insulin secretion, while alpha-cell glucagon release is suppressed; because both effects are glucose-dependent, intrinsic hypoglycemia risk is low when the drug is used alone [1][2]. Its defining feature, however, is a pronounced and sustained slowing of gastric emptying. This gives lixisenatide a comparatively strong effect on post-prandial glucose excursions and a relatively modest effect on fasting glucose — the signature of a short-acting, or \"prandial,\" GLP-1 agonist, which is why it is dosed before a meal rather than at a fixed time like long-acting weekly agents [1][2].\n\nPharmacokinetically, subcutaneous lixisenatide reaches peak plasma concentration (Tmax) at a median of 1 to 3.5 hours and has a mean terminal half-life of approximately 3 hours after multiple dosing in patients with type 2 diabetes (Cmax around 84 pg/mL after a 20 mcg dose) [1][2]. It is eliminated mainly by glomerular filtration followed by tubular reabsorption and proteolytic degradation, so exposure rises in renal impairment and the drug is not recommended in end-stage renal disease [1]. Being an exendin-based peptide, lixisenatide is also relatively immunogenic: a majority of treated patients develop anti-drug antibodies, which in a minority with very high titers can attenuate the glucose-lowering response [1].\n\nThe 10 mcg → 20 mcg titration is pharmacodynamically deliberate: starting low for 14 days lets the gut adapt to delayed emptying, markedly reducing nausea and vomiting before the full 20 mcg maintenance dose is reached [1][3]. Downstream, sustained agonism lowers HbA1c by roughly 0.7–1.0%, trims post-meal glucose peaks, and produces modest weight loss [3][6]. Lixisenatide crosses the blood–brain barrier, which underpins its investigational study in early Parkinson's disease, where GLP-1 signaling is hypothesized to be neuroprotective [5].
Clinical Trial Efficacy Highlights
- starGetGoal-Mono (Fonseca et al., Diabetes Care 2012) randomized 361 patients with type 2 diabetes on no glucose-lowering therapy to once-daily lixisenatide (10 mcg titrated to 20 mcg) or placebo for 12 weeks. Lixisenatide reduced HbA1c by 0.54% (2-step titration) to 0.66% (1-step) more than placebo (P < 0.0001), with about 22% of treated patients reporting nausea — establishing monotherapy efficacy and the basis for the 10→20 mcg titration [3].
- starGetGoal-M (Ahrén et al., Diabetes Care 2013) added lixisenatide 20 mcg or placebo to metformin and compared morning versus evening injection. HbA1c fell by 0.9% with morning dosing and 0.8% with evening dosing versus 0.4% with placebo, and roughly 40% of treated patients reached HbA1c below 7.0%, showing that timing relative to a meal — not specifically the morning — drives the effect [6].
- starELIXA (Pfeffer et al., NEJM 2015) was the first dedicated cardiovascular outcomes trial of a GLP-1 receptor agonist. It enrolled 6,068 patients with type 2 diabetes and a recent acute coronary syndrome, followed for a median of about 25 months. The primary composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina occurred in 13.4% on lixisenatide versus 13.2% on placebo (HR 1.02, 95% CI 0.89–1.17) — demonstrating cardiovascular safety (noninferiority) but not superiority [4].
- starAcross the Phase 3 GetGoal program, lixisenatide consistently lowered HbA1c by roughly 0.7–1.0% from baseline and produced its largest reductions in post-prandial plasma glucose, reflecting the marked gastric-emptying delay characteristic of a short-acting GLP-1 agonist, alongside modest body-weight reductions [2][3][6].
- starLIXIPARK (Meissner et al., NEJM 2024) was a 12-month, randomized, double-blind, placebo-controlled Phase 2 trial in 156 patients with early Parkinson's disease. The MDS-UPDRS part III motor score changed by −0.04 with lixisenatide versus +3.04 with placebo (between-group difference 3.08, 95% CI 0.86–5.30; P = 0.007), suggesting slowed motor progression; however gastrointestinal effects were common (nausea 46%, vomiting 13%) and lixisenatide is not approved for Parkinson's disease [5].
- starPharmacokinetic and receptor characterization (Barnett, Core Evidence 2011) confirms a GLP-1 receptor affinity roughly four-fold that of native GLP-1 (IC50 ≈ 1.4 nM), a Tmax of about 1–2 hours, and a half-life of 2–4 hours, supporting once-daily prandial dosing and a predominantly post-prandial glucose-lowering profile [2].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal effects are the most common adverse events: nausea (dose-dependent, roughly 20–25% in type 2 diabetes trials and as high as 46% on the 20 mcg dose in the LIXIPARK Parkinson's trial), vomiting, and diarrhea. Most are mild-to-moderate and are minimized by the 14-day 10 mcg lead-in before the 20 mcg maintenance dose [1][3][5].
- warningHypoglycemia is uncommon with lixisenatide monotherapy because insulin release is glucose-dependent, but risk rises substantially when it is combined with a sulfonylurea or insulin; the label advises reducing the sulfonylurea or insulin dose [1].
- warningAcute pancreatitis is a recognized class risk for GLP-1 receptor agonists. Patients with persistent severe abdominal pain should stop the drug and be evaluated, and it should not be restarted if pancreatitis is confirmed [1].
- warningBecause lixisenatide is an exendin-based peptide, it is relatively immunogenic: most patients develop anti-drug antibodies, and a minority with very high antibody titers may show an attenuated glucose-lowering response. Hypersensitivity reactions, including rare anaphylaxis and angioedema, have been reported [1].
- warningRenal effects: lixisenatide is cleared renally, and acute kidney injury (sometimes requiring dialysis) has been reported, usually in the setting of dehydration from nausea, vomiting, or diarrhea. It is not recommended in severe renal impairment or end-stage renal disease, and should be used cautiously when eGFR is 15–29 mL/min [1].
- warningDelayed gastric emptying can slow the absorption of orally administered drugs; time-sensitive oral medications (such as certain antibiotics or oral contraceptives) should be taken at least one hour before the injection, and lixisenatide is not recommended in patients with gastroparesis [1].
- warningUnlike human GLP-1 analogues such as liraglutide and semaglutide, the Adlyxin label does not carry a boxed warning for thyroid C-cell tumors; nonetheless, general GLP-1-class caution applies and any persistent symptoms should be evaluated by a clinician [1].
- warningRegulatory and research status: lixisenatide was FDA-approved (Adlyxin, 2016) and EMA-approved (Lyxumia, 2013) but was discontinued in the US in January 2023 and had its EU authorisation withdrawn, both for commercial rather than safety reasons [7][8]. Research-grade lyophilized vials are sold strictly for laboratory use and are not a substitute for a prescribed product; the protocol here is educational and is not medical advice.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Lixisenatide dosage?expand_more
The typical Lixisenatide dosage is a two-step, once-daily titration: 10 mcg subcutaneously once daily for the first 14 days, then 20 mcg once daily as the maintenance dose beginning on Day 15. The injection is given within one hour before the first meal of the day. The 14-day lead-in at 10 mcg exists to let the gut adapt and to reduce nausea before the full 20 mcg dose. Commercially, lixisenatide came as a 50 mcg/mL green starter pen (for the 10 mcg phase) and a 100 mcg/mL burgundy maintenance pen (for the 20 mcg phase).
Is Lixisenatide FDA approved?expand_more
Lixisenatide was FDA-approved in July 2016 as Adlyxin, an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and was earlier approved by the EMA as Lyxumia in 2013. However, Sanofi discontinued Adlyxin in the United States as of January 1, 2023, and the EU marketing authorisation for Lyxumia was subsequently withdrawn — both for commercial rather than safety or efficacy reasons. The fixed-ratio combination of insulin glargine plus lixisenatide (Soliqua/Suliqua) remained on the market. Research-grade lixisenatide vials are sold for laboratory use only and are not FDA-approved products.
What is the half-life of Lixisenatide?expand_more
Lixisenatide has a mean terminal half-life of approximately 3 hours following subcutaneous dosing in patients with type 2 diabetes (reviews cite a 2–4 hour range), with peak plasma concentration reached at a median of 1 to 3.5 hours. This short, prandial profile is why it is taken once daily before a meal and why its main glucose-lowering effect is on post-meal (post-prandial) blood sugar — in contrast to long-acting weekly agents such as semaglutide. It is cleared largely by the kidneys, so exposure increases in renal impairment.
How do you reconstitute Lixisenatide from a research vial?expand_more
Draw 3 mL of bacteriostatic water and inject it slowly down the inner wall of a 1 mg vial to make roughly 333 mcg/mL (0.33 mg/mL). Swirl gently until clear — never shake. On a U-100 insulin syringe, 10 mcg measures 3 units (0.03 mL) and 20 mcg measures 6 units (0.06 mL), so the initiation and maintenance doses both land on clean marks. Store the reconstituted solution at 2–8 °C and use it within about 14–28 days. Commercially, lixisenatide instead came as a ready-to-use prefilled pen (50 or 100 mcg/mL).
What are the most common Lixisenatide side effects?expand_more
The most common Lixisenatide side effects are gastrointestinal — nausea, vomiting, and diarrhea — which are dose-dependent and are reduced by the 14-day 10 mcg lead-in before the 20 mcg maintenance dose. Headache and injection-site reactions are also reported. More serious but less common risks include acute pancreatitis, acute kidney injury (usually from dehydration due to vomiting/diarrhea), hypoglycemia when combined with a sulfonylurea or insulin, and hypersensitivity reactions. Because lixisenatide is an exendin-based peptide, most users develop anti-drug antibodies, which rarely blunt its effect at very high titers.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Lixisenatide, plus the universal dosing calculator.
Academic References & Study Citations
FDA Prescribing Information — ADLYXIN (lixisenatide) injection, for subcutaneous use, Sanofi (Initial U.S. Approval 2016). Dosing (10 mcg ×14 days then 20 mcg once daily before first meal), clinical pharmacology (terminal half-life ~3 h, Tmax 1–3.5 h), mechanism, warnings. DailyMed. View Scientific Paper →
Barnett AH. (2011) Core Evid 6:67-79. 'Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.' Structure (44-aa exendin-4 analogue), GLP-1 receptor affinity (IC50 ~1.4 nM, ~4× native GLP-1), half-life 2–4 h, Tmax 1–2 h. View Scientific Paper →
Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. (2012) Diabetes Care 35(6):1225-1231. 'Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy' (GetGoal-Mono). HbA1c −0.54% to −0.66% vs placebo. View Scientific Paper →
Pfeffer MA, Claggett B, Diaz R, et al. (2015) N Engl J Med 373(23):2247-2257. 'Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome' (ELIXA). 6,068 patients; primary CV composite HR 1.02 (95% CI 0.89–1.17). View Scientific Paper →
Meissner WG, Remy P, Giordana C, et al. (2024) N Engl J Med 390(13):1176-1185. 'Trial of Lixisenatide in Early Parkinson's Disease' (LIXIPARK). MDS-UPDRS III −0.04 vs +3.04 placebo at 12 months (difference 3.08, P = 0.007). View Scientific Paper →
Ahrén B, Leguizamo Dimas A, Miossec P, et al. (2013) Diabetes Care 36(9):2543-2550. 'Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin' (GetGoal-M). HbA1c −0.9% (AM)/−0.8% (PM) vs −0.4% placebo. View Scientific Paper →
European Medicines Agency — Lyxumia (lixisenatide) EPAR. Initial authorisation 31 January 2013; marketing authorisation withdrawn 18 December 2025 at the manufacturer's request for commercial reasons. View Scientific Paper →
Min JS, Jo SJ, Lee S, et al. (2025) Drug Des Devel Ther 19:3509-3537. 'A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.' Notes lixisenatide withdrawn from the US market as of 1 January 2023 for commercial reasons. View Scientific Paper →